Premium
P4‐300: New exploratory Alzheimer's drug anavex 2‐73 changes in electrophysiological markers in Alzheimer's disease: First patient data from an ongoing phase 2a study in mild‐to‐moderate Alzheimer's patients
Author(s) -
Macfarlane Stephen,
Cecchi Marco,
Moore Dennis,
Zografidis Tasos,
Missling Christopher
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.08.130
Subject(s) - p3b , donepezil , p3a , electroencephalography , psychology , audiology , event related potential , cognition , montreal cognitive assessment , medicine , disease , dementia , neuroscience , cognitive impairment
References Conclusions Primary: Evaluate the maximum tolerated dose of ANAVEX2-73. Secondary: Dose response, bioavailability, exploratory cognitive efficacy using electroencephalographic (EEG) activity, including event-related potentials (EEG/ERP), Mini Mental State Examination (MMSE), Cogstate and evaluation of ADSC-ADL and add-on therapy to donepezil, the current standard of care. PART B is an open-label extension for an additional 26 weeks, with daily oral dosing so as to establish a longer drug effect.